相关实验视频

Updated: Jul 23, 2025

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

在乳腺癌进展期间,HER2-低表达的动态

Sarah Anderson¹, Brooke Baxter Bartow¹, Gene P Siegal¹

¹Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA.

Breast cancer research and treatment

|July 11, 2023

概括

乳腺癌 (BC) 中的HER2表达是动态的,常常在原发性瘤和转移性瘤之间发生变化. 了解这些低HER2的变化对于有效的治疗计划至关重要.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物标志物研究生物标志物研究

背景情况:

低人体表皮生长因子受体2 (HER2) 表达是乳腺癌 (BC) 的新兴治疗点.
抗体-药物结合物Trastuzumab deruxtecan的目标是HER2-低BC.
在BC进展期间描述HER2表达动态对于治疗策略至关重要.

研究的目的:

研究从原发性乳腺癌 (pBC) 到转移性乳腺癌 (mBC) 的HER2表达水平的变化.
评估HER2表达异质性在BC进展中的临床意义.

主要方法:

在171个配对的初级和转移性BC样本中评估HER2表达.
在评估中包括低HER2类别.
分析HER2-0,HER2-低和HER2-阳性状态之间的转化率.

主要成果:

低HER2的病例占pBCs的25.7%和mBCs的23.4%.
观察到HER2-0和HER2-low之间的整体转化率为31.7%,HER2-low到HER2-0更为频繁.
在初级和转移部位之间以及不同转移部位之间注意到HER2状态的显著不一致.

结论:

低HER2的乳腺癌是一个异质的群体,具有动态的HER2表达.
在初级和晚期疾病之间HER2状态的显著不一致性需要重复生物标志物测试.
在晚期疾病中重复生物标志物研究对于准确医学中个性化治疗规划至关重要.

关键词:

放大功率是指放大功率是指放大功率.乳腺癌是什么? 乳腺癌是什么在HER2-低的水平下.免疫组织化学免疫组织化学在现场混合化.过度表达是一种过度表达.

更多相关视频

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

相关概念视频

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...